Our Technology

Due to the recent pandemic our research has shown that there are many disadvantages to the standard PCR tests. The team introduced in this context has been dedicated to this project since the onset of the epidemic in the summer of 2020. As soon as team members initially deliberated on the idea of a new method for detecting viruses. We embarked on a structured journey to advance this important project. This diagnostic process included the formulation of a custom enzyme blend, the establishment of a viral isolation procedure, and the design of an electronic tool for virus detection. Additionally, we researched during the development phase to assist in addressing challenges associated with spectrometric analysis of materials.In addition to submitting the patent application, we obtained certifications for both the device and the methodology. We possess the CE certificate as well as the IVD certificate, indicating compliance with relevant quality and safety standards.Numerous specialists from various fields dedicated extensive research to the project during its development phase

Specialized

The Rapid Viral Check Platform: New Virus Testing TechnologyCost-effective, with a 70% reduction in expenses compared to PCR.Significantly shorter time to results. Eliminates intermediate results; delivers clear, binary outcomes - positive or negative.No need for costly laboratory equipment.User-friendly, designed for operation by trained medical personnel, removing the need for highly skilled lab technicians.

Rapid diagnostic assays for

  • new SARS-CoV-2 strains
  • other respiratory viruses
  • Mycobacterium tuberculosis
  • metabolic disorders
  • monitoring animal and plant pathogens
  • Laboratory

    Laboratory studies to complex high-tech testing.

  • Modern equipment

    Diagnostic equipment to comply with international requirements.

The Rapid Viral Check Platform: New Virus Testing Technology

Cost-effective, with a 70% reduction in expenses compared to PCR.Significantly shorter time to results.Eliminates intermediate results; delivers clear, binary outcomes - positive or negative.No need for costly laboratory equipment.User-friendly, designed for operation by trained medical personnel, removing the need for highly skilled lab technicians.

  • Nick Peronace

    CEO

  • Kenny Toye

    General Manager

  • Borut Kostanjevec

    International Business Development

  • Tadej Tofant

    Biotech AI Specialist

  • Tomaž Buedeled, BSc

    Senior Research Scientist, Faculty of Medicine

  • Dr. Zeljko Perdija

    Internal Medicine

  • Tarig Abdellatief

    COO

  • Dr. Tanja Bagar

    Doctorate in microbiology

Contact form